Mirum Pharmaceuticals (MIRM) Total Current Liabilities (2018 - 2026)

Mirum Pharmaceuticals' Total Current Liabilities history runs 9 years deep, the most recent figure standing at $272.8 million for Q1 2026.

• On a quarterly basis, Total Current Liabilities rose 113.85% year-over-year to $272.8 million in Q1 2026; TTM through Mar 2026 was $272.8 million, a 113.85% increase from a year earlier, with the FY2025 full-year figure at $205.8 million, up 62.62% from the prior year.
• Total Current Liabilities climbed to $272.8 million in Q1 2026 per MIRM's latest filing, from $205.8 million in the prior quarter.
• Across five years, Total Current Liabilities topped out at $272.8 million in Q1 2026 and bottomed at $34.6 million in Q1 2022.
• The 5-year median for Total Current Liabilities is $105.9 million (2024), against an average of $108.0 million.
• Across the five-year window, Total Current Liabilities slipped 1.34% in 2022 and surged 116.84% in 2024, its largest moves.
• Year by year, Total Current Liabilities stood at $64.7 million in 2022, then surged by 34.51% to $87.1 million in 2023, then soared by 45.35% to $126.6 million in 2024, then soared by 62.62% to $205.8 million in 2025, then soared by 32.57% to $272.8 million in 2026.
• Per Business Quant, the three latest MIRM Total Current Liabilities figures stand at $272.8 million (Q1 2026), $205.8 million (Q4 2025), and $160.4 million (Q3 2025).